Forum Ventures

Lux Capital is a venture fund that invests in emerging science and technology ventures at the outermost edges of what is possible. We partner with bold entrepreneurs who are challenging the status of quo - and we are willing to bet on them when no-one else can or will. Our team is comprised of neuroscientists, chemists, data scientists, computational biologists, economists, electrical engineers, machine-learning hackers and philosophers. Lux Capital was founded by Peter Hebert, Robert Paull and Josh Wolfe in the year 2000 and has its headquarters in New York with an additional Silicon Valley office.

Canaan Partners is an early-stage venture capital firm investing in technology and healthcare companies in the United States.

Notable Capital is a US venture capital firm that partners with early-stage technology founders. It became the independent US-focused successor to GGV Capital in March 2024, while GGV Capital's Asian operations rebranded as Granite Asia. The firm reports more than 25 years of experience and over USD 5 billion in assets under management.

FirstMark Capital is an early stage venture capital firm based in New York that primarily invests at the seed or Series A stage. We are proud to back the ambitious founders of the most iconic companies in the world. We provide our investee companies access to the FirstMark platform and resources, which we believe is powered by the largest network in venture capital. FirstMark was founded in 2008 as a spinoff of Pequot Ventures, owned Pequot Capital Management.

Northzone is a European early-stage venture capital fund that invests in innovative consumer and enterprise companies in Europe and the US East Coast,. We invest primarily at the Series A and B stage, but selectively pursue seed investments. We have deep, long-standing technology expertise and benefit from the fact that the majority of our investment team have previously founded companies.

Greycroft Partners is a New York based venture capital firm with a flexible, long term investment approach. We can invest at any stage of a startup's lifecycle, and have separate funds that invest at earlier stages ($100K to $5m first cheque, with follow-on rounds up to $10m) and later stage pre-IPO rounds ($10m first cheque, up to $35m total). Greycroft is flexible on ownership percentage, check size, and board seats which means we can bring together syndicates that may be impossible with the stricter requirements of other funds. We are truly long-term, and we often hold investments for over ten years. Although we have a greater number of investments in the US, we can and have invested globally, including Europe and Asia. Our portfolio companies benefit from active, hands-on assistance from the partners. Greycroft's partners work as a team, which means our CEOs have access to the collective rolodex and expertise of the entire partnership. We leverage an extensive network of media and technology connections to help you gain visibility, build strategic partnerships, and successfully exit.

Versant Ventures is a venture capital fund focused on biotechnology and life sciences, with a primary focus on novel therapeutics targeting important unmet medical needs. Versant Ventures both develops its own projects, and invests in external companies. In both instances we provide the necessary funds to bring the product to launch. We have a large team of scientists, known as our Discovery Engines, which develop and validate new biological discoveries and technologies. We also invest in externally developed IP in companies throughout the United States, Canada and Europe.

Winklevoss Capital is a venture capital firm focused on early-stage startups, with stated focus areas in crypto, space, energy and bio.

Innovation Endeavors is a venture capital firm focused on visionary founders, transformational technology and emergent ecosystems for a new world. Innovation Endeavors was co-founded by Eric Schmidt (ex-CEO and Chairman of Google), who remains an anchor investor, and merged with Herzilya, an Israel-based fund, in August 2017. Innovation Endeavors has offices in Silicon Valley, Tel Aviv and New York, and focuses its investment efforts on North America, Europe and the Middle East.

Lerer Hippeau is an early-stage venture capital fund headquartered in New York. Lerer Hippeau was founded by Ken and Ben Lerrer, co-founders of the Huffington Post and Thrillist respectively, and the majority of our team consists of fellow startup founders and operators. We look to invest in entrepreneurs with product vision, consumer insight, focused execution, and unwavering ambition. Historically, we have invested primarily in early-stage companies based in New York (although we are not limited to NY), and almost exclusively headquartered in the United States.

Union Square Ventures is a small collegial partnership based in New York that manages over $1B across seven technology-focused venture funds. Union Square Ventures is one of the most successful venture funds in the world and has been an early-stage investor in some of America's most successful startups such as Zynga, Indeed, Tumblr, Twitter, Lending Club, Etsy, Twilio and MongoDB. USV was founded in 2003 by Fred Wilson and Brad Burnham.

Octopus Ventures is one of Europe's most active experienced venture capital firms, and has invested in more than 100 companies since its 1999 founding. Octopus Ventures invests in both enterprise and consumer-focused startups, and participates from Seed (typical investment $1m) to Series A (typical investment $4m). Our team knows what it is like on the other side of the fence. Before joining Octopus, many of the team established themselves in other industries, from consumer goods and professional services to technology and telecoms, and several launched and sold their own startups.

New Leaf Venture Partners is an early and growth-stage investor exclusively focused on healthcare technology. We invest across four sectors of healthcare technology: biopharmaceuticals, information convergence, medical devices and life science tools. In Biopharmaceuticals we invest from seed (creation) stage through to IPO and beyond. We look for large unmet medical needs, strong science, well differentiated technologies, and high-quality pre-clinical and clinical development programs. In Information Convergence (which includes healthcare IT, tools and diagnostics) we invest from early stages through to companies with revenues of $100m+. We have a similar approach in Medical Devices (where we look for important medical devices with the power to reduce costs and improve efficiencies in the healthcare system) and Life Sciences (where we look for products that accelerate the discovery process, uncover novel insights into the biology of disease and health, and personalize diagnoses and treatment).

SOSV is a venture capital manager investing in deep-tech companies from pre-seed through follow-on rounds. It also operates founder programs including HAX, SOSV SF and SOSV NY.

NextView Ventures is a seed-stage venture firm headquartered in Boston. Nextview invests in technology driven companies redesigning what we call the Everyday Economy, which encompasses a wind range of startups primarily (but not only) focused on serving consumers, including in food, housing, apparel, transport, health, work, money and entertainment. We invest at the pre-seed and seed stage and usually invest before meaningful traction. Nextview was founded in 2010 by Dave Beisel (previously Venrock), Rob Go (Spark Capital) and Lee Hower (Judith Capital). Nextview Ventures raised its first $21m fund in 2012, a $40m fund in 2014 and a $50m fund in 2017.

Correlation Ventures is a venture capital firm that specialises in co-investing with other venture firms. We use analytics from an in-house database of venture capital financings and portfolio company returns to assist our investment decisions, and rely on this data instead of intuition in our investment decisions. We provide fast access to capital, making investment decisions in under two weeks, and are very flexible on terms and investment size. Correlation Ventures only invests in private, US-headquartered companies, and we only invest where at least one venture firm co-investing in the round is also making its first investment in the company.